Phase 3 Trial of Regorafenib as Adjuvant Therapy in Colon Cancer

Share this content:
Researchers are investigating the efficacy of regorafenib in prolonging DFS among patients with stage IIIB or IIIC colon cancer compared with placebo.
Researchers are investigating the efficacy of regorafenib in prolonging DFS among patients with stage IIIB or IIIC colon cancer compared with placebo.

Title: A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer1

Principal Investigator: Norman Wolmark, MD, NSABP Foundation

Description: For this randomized, double-blind phase 3 study, researchers are investigating the efficacy of regorafenib in prolonging disease-free survival (DFS) among patients with stage IIIB or IIIC colon cancer compared with placebo.

Eligible patients must have completed at least 4 months of a standard adjuvant therapy, including 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX), capecitabine and oxaliplatin (CapeOx), or others.

Patients will receive placebo or regorafenib 120 mg once daily for 3 weeks of a 4 week cycle for 2 years.

The primary endpoint is 10-year DFS. Secondary outcomes include overall survival, assessments of toxicity, 2-year compliance, correlative science (biomarkers, pharmacodynamics, pharmacokinetics), and comparative evaluation of treatment-related adverse events among patients receiving regorafenib and placebo.

The estimated enrollment is 1118 patients.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/study/NCT02664077.

Status: This study is open and recruiting patients as of September 25, 2017.

This study is sponsored by NSABP Foundation, Inc in collaboration with Bayer.

Reference

  1. Clinicaltrials.gov. A study evaluating regorafenib following completion of standard chemotherapy for patients with colon cancer (ARGO). NCT02664077. https://clinicaltrials.gov/ct2/show/study/NCT02664077. Accessed September 25, 2017. 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters